Loading clinical trials...
Loading clinical trials...
Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN 1401)
Conditions
Interventions
Tumor Cell Collection
Autologous Stem Cell Transplant
+5 more
Locations
15
United States
University of California, San Francisco
San Francisco, California, United States
Emory University
Atlanta, Georgia, United States
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Start Date
July 1, 2016
Primary Completion Date
June 30, 2020
Completion Date
December 9, 2022
Last Updated
May 7, 2024
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions